Matinas BioPharma (NYSE: MTNB) reported Q1 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.